Major Depressive Disorder

As the FDA strengthens AI standards after its recent meeting, a new AI-assisted genetic tool shows promise for pinpointing patients who may respond to a vasopressin blocker.

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

This month in review highlights November’s biggest psychiatry stories, including FDA moves, phase 4 findings, and new data on digital mental health tools.

A study showed that users readily adopt mental health apps, but adherence and follow-up completion lag; reminders and human support improve engagement.

Phase 4 double-blind data reveal improved remission, but no significant difference in response between perospirone and placebo.

FDA clears BrainsWay's Deep TMS for adolescents aged 15-21 years with major depressive disorder (MDD), expanding its use.

This month in review spotlights the top psychiatry news from October 2025, featuring FDA's approval of UZEDY for bipolar I disorder.

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Study finds repetitive transcranial magnetic stimulation brings clinically meaningful improvements in quality of life for adults with MDD through 12 weeks.

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

Therapist Diana Guzman, LMHC, writes about attempting suicide despite counseling patients battling with suicidal ideation.

Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

Check out the top 5 psychiatry headlines in August 2025, including the fast-track designation of NRX-100 for suicidal ideation.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

Phase 2 data shows meaning-centered psychotherapy may strengthen psilocybin-assisted therapy for depression in patients with cancer and MDD.

In a new study, esketamine nasal spray improved anhedonia in treatment-resistant unipolar and bipolar depression, independent of general symptom changes.

A recent study shows combined treatment increases total and N3 sleep in just 3 days for patients with comorbid insomnia and depression.

Single-dose psychedelic therapy (RE104 30 mg) shows rapid improvements in postpartum depression, offering a potential alternative to slow-acting therapies.